VivoSeq
Oncology

Breast Neoplasm Female

1

Pipeline Programs↗

1

Active Trials↗

2

Companies Involved↗

Breast Neoplasm Female is an early-stage landscape with 1 program across 2 companies. The most active players are Teva, Ontario Clinical Oncology Group (OCOG).

Intelligence

Pipeline Metrics

Competitive Density

14/100

Pipeline Velocity

0/100

Mech. Concentration

100/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Teva logo

Teva

1 program

Phase 2O

Ontario Clinical Oncology Group (OCOG)

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 21

Disulfiram

Teva

Phase 3
No programs
Approved
No programs

Analysis

Trial Status

2

clinical trials

Recruiting1 · 50%
Completed1 · 50%

Clinical Trials

Trial Activity

A Randomized Trial of Five-Fraction Partial Breast Irradiation (RAPID2)
Recruiting·OOntario Clinical Oncology Group (OCOG)·Phase 3·NCT05417516·910 enrolled
Phase II Open Labeled Trial of Disulfiram With Copper in Metastatic Breast Cancer
Completed·TThe Institute of Molecular and Translational Medicine, Czech Republic·Phase 2·NCT03323346·9 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)